INTRODUCTION AND OBJECTIVE: @entity3457 ( @entity3457 ) is an option for the management of favorable @entity263 (CaP) in the PSA era. Published studies have reported variable inclusion criteria for cohort selection. Accurate assessment of individual @entity1 risk in @entity3457 is dependent not only upon rigorous selection criteria, but also reliability of diagnosis at tissue biopsy. To date, the impact of immediate transrectal ultrasound (TRUS) rebiopsy in confirming candidates for @entity3457 has been incompletely defined. METHODS: From a total of over 567 @entity1 , 67 met criteria for @entity3457 (Gleason <7, PSA <10, PSAD <0.15, <3 cores with <50% involvement of any 1 core). Fifty-two @entity1 agreed to a 12-core TRUS rebiopsy within 6 months of first diagnosis performed in clinic. Statistical analysis was performed using Wilcoxon signed rank test and logistic regression to determine predictors of rebiopsy characteristics, histopathologic outcomes, and impact on treatment choice. RESULTS: Mean cohort age was 63.9 years (range 56-72 years), PSA 5.9 ng/ml (4.1-10), and PSA density 0.12 ng/ml/cc at initial biopsy. @entity5 involved 1.1 cores and 3.2% (range 1%-5%) of the total tissue. Average time to rebiopsy was 2.7 months. Notably, 29 of 52 @entity1 (56%) demonstrated no evidence of CaP on repeat biopsy; 14 of 23 @entity1 with a positive repeat biopsy showed either an increase in @entity5 volume (2.8% mean increase) and 9 (18%) were upgraded to Gleason pattern 3+4 = 7. Rebiopsy demonstrated 9 (17%) @entity1 exceeded @entity3457 criteria. Nine @entity1 chose curative surgical intervention (radical prostatectomy) based on increased @entity5 volume or grade (4) or an elective desire for treatment (5). All had organ confined disease with negative margins on final pathologic analysis. Statistical review revealed that initial Gleason score, PSA density, and number of positive cores at first biopsy were not predictive of @entity1 with higher volume/grade on re-biopsy. CONCLUSIONS: Immediate TRUS repeat biopsy after diagnosis frequently fails to @entity263 confirming the favorable-risk nature of disease burden in this group being considered for @entity3457 . A subset of @entity1 are upgraded (17%) leading to reconsideration of @entity3457 . We conclude this clinic-based approach provides valuable additional information to discriminate appropriate @entity3457 candidates.

Impact of immediate TRUS rebiopsy in a @entity1 cohort considering active surveillance for favorable XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Tumor'] @entity263 :: ('MESH:D011471', 'Disease') :: ['redemonstrate prostate cancer', 'risk prostate cancer'] @entity3457 :: ('OMIM:612348', 'Disease') :: ['AS', 'Active surveillance']
@entity263 :: (MESH:D011471,Disease) :: ['risk prostate cancer']
